Skip to main content
Premium Trial:

Request an Annual Quote

Lee Bendekgey, Vladimir Vapnik, Ken Welsh

Premium

Lee Bendekgey has joined Nuvelo as senior vice president and general counsel. Bendekgey was previously at Incyte, where he held several executive positions, including executive vice president, general counsel, acting chief financial officer, and acting general manager of the company’s information business. Prior to Incyte, Bendekgey worked for Silicon Graphics, where he held a variety of positions in SGI’s legal group.


Health Discovery Corporation, a systems biology-based biomarker discovery company, has appointed Vladimir Vapnik and Ken Welsh to its scientific advisory board. Vapnik led the machine learning research department at the Institute of Control Sciences in Moscow, where he worked from 1965 to 1990. In the US, he worked at AT&T Bell Laboratories. Welsh is currently a professor of clinical genomics at Royal Brompton Hospital and a scientific advisor to the West London Transplant Center.

Filed under

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.